Psyence Group Inc. (CSE:PSYG)
Canada · Delayed Price · Currency is CAD 0.1500
+0.0100 (7.14%)
Jul 18, 2025, 2:06 PM EDT
Psyence Group Company Description
Psyence Group Inc., a life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom.
It operates in two segments: Clinical Trial Activities and Non-Clinical Trial Activities. The company natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions.
It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand.
The company was founded in 2019 and is based in Toronto, Canada.
Psyence Group Inc.
| Country | Canada |
| Founded | 2019 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
Contact Details
Address: 121 Richmond Street West Toronto, Ontario M5H 2K1 Canada | |
| Phone | 416-477-1708 |
| Website | psyence.com |
Stock Details
| Ticker Symbol | PSYG |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| ISIN Number | CA74449Q1063 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jody Aufrichtig | Co-Founder and Executive Chairman |
| Adri Botha | Interim Chief Financial Officer |
| Taryn Vos | General Counsel |
| Tony Budden | Chief Strategy Officer |
| Mary-Elizabeth Gifford | Executive Vice President for Public Policy and Global Impact |